Market closed

Novavax/$NVAX

14:30

16:10

17:45

19:25

21:00

1D1W1MYTD1Y5YMAX

About Novavax

Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. Novavax works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The Company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from Europe.

Ticker

$NVAX

Sector

Health Care

Trading on

NASDAQ

Industry

Biotechnology

Headquarters

Gaithersburg, United States

Employees

1,543

Website

www.novavax.com

Novavax Metrics

BasicAdvanced

$1.4B

-

-$1.99

2.09 -

Price and volume

Market cap

$1.4B

Beta

2.09

52-week high

$23.86

52-week low

$3.53

Average daily volume

4.1M

Financial strength

Current ratio

0.935

Quick ratio

0.89

Long term debt to equity

-47.974

Total debt to equity

-49.811

Interest coverage (TTM)

-17.46%

Management effectiveness

Return on assets (TTM)

-10.76%

Return on equity (TTM)

47.29%

Valuation

Price to revenue (TTM)

1.391

Price to book

-2.62

Price to tangible book (TTM)

-2.11

Price to free cash flow (TTM)

-10.96

Growth

Revenue change (TTM)

-15.68%

Earnings per share change (TTM)

-67.45%

3-year revenue growth (CAGR)

-9.74%

3-year earnings per share growth (CAGR)

-48.93%

What the Analysts think about Novavax

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Novavax stock.

Novavax Financial Performance

Income Statement

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37B

-39.75%

Net income

$45B

107.52%

Profit margin

37.65%

6.78%

Novavax Earnings Performance

Earnings per share (EPS)

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

-

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

-

Novavax News

AllArticlesVideos

Here's why vaccine stocks are surging in 2025

Finbold·7 days ago

Novavax to sell Czech manufacturing unit to Novo Nordisk for $200 mln

Reuters·1 month ago

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novavax, Inc. - NVAX

Accesswire·2 months ago

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $NVAX

$

Capital at risk

Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Novavax stock?

Novavax (NVAX) has a market cap of $1.4B as of January 15, 2025.

What is the P/E ratio for Novavax stock?

The price to earnings (P/E) ratio for Novavax (NVAX) stock is 0 as of January 15, 2025.

Does Novavax stock pay dividends?

No, Novavax (NVAX) stock does not pay dividends to its shareholders as of January 15, 2025.

When is the next Novavax dividend payment date?

Novavax (NVAX) stock does not pay dividends to its shareholders.

What is the beta indicator for Novavax?

Novavax (NVAX) has a beta rating of 2.09. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.